Journal of Antimicrobial Chemotherapy (2001) 47, 505-511
© 2001 The British Society for Antimicrobial Chemotherapy
Review |
Activity of phenothiazines against antibiotic-resistant Mycobacterium tuberculosis: a review supporting further studies that may elucidate the potential use of thioridazine as anti-tuberculosis therapy
a Unit of Mycobacteriology and c Unit of Clinics of Tropical Diseases, Institute of Hygiene and Tropical Medicine, Universidade Nova de Lisboa, Lisbon, Portugal; b Department of Microbiology, Sonderborg Sygehus, Sonderborg, Denmark
The in vitro and in vivo anti-mycobacterial activities of a number of phenothiazine compounds are reviewed. These compounds, normally employed for the management of psychosis, inhibit the growth in vitro of Mycobacterium tuberculosis at concentrations that are significantly greater than those that can safely be achieved in a patient harbouring these infections. Nevertheless, one of these phenothiazines, chlorpromazine, is concentrated by human macrophages to 10–100 times its concentration in plasma, and has activity against mycobacteria that have been phagocytosed by these cells. Phenothiazines have significant in vitro activity against susceptible, polydrug- and multidrug-resistant strains of M. tuberculosis, as well as enhancing the activity of some agents employed for first-line treatment. Because thioridazine, the very mild anti-psychotic agent whose most common side effect is drowsiness, has equal anti-tuberculosis properties in vitro to chlorpromazine, we recommend that thioridazine be studied as an adjuvant to the four- or five-drug regimens employed for the management of a freshly diagnosed tuberculosis infection of unknown antibiotic susceptibility, at least during the period required for the assessment of antibiotic susceptibility. Because it also enhances the activity of rifampicin and streptomycin, antibiotics that frequently have adverse effects, additional studies evaluating the use of thioridazine as an adjuvant may eventually allow a reduction in the dosages of these antibiotics and result in a decreased frequency of adverse effects. It is important to note that whereas the management of patients with thioridazine for periods in excess of many months will result in the appearance of some undesirable side effects, its use for a limited period of 2–3 months should not produce side effects that are more severe than simple drowsiness. Nevertheless, further in vitro and in vivo studies are essential before thioridazine may be recommended for the management of select cases of pulmonary tuberculosis.
* Correspondence address. Instituto de Higiene e Medicina Tropical, Universidade Nova de Lisboa, Rua Junqueira 96, 1349-008 Lisbon, Portugal. Tel: +351-21-365-26-53; Fax: +351-21-363-21-05; E-mail: lamaral{at}ihmt.unl.pt
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  C. D. Sohaskey Nitrate Enhances the Survival of Mycobacterium tuberculosis during Inhibition of Respiration J. Bacteriol., April 15, 2008; 190(8): 2981 - 2986. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Amaral, M. Martins, and M. Viveiros Enhanced killing of intracellular multidrug-resistant Mycobacterium tuberculosis by compounds that affect the activity of efflux pumps J. Antimicrob. Chemother., June 1, 2007; 59(6): 1237 - 1246. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Ramon-Garcia, C. Martin, J. A. Ainsa, and E. De Rossi Characterization of tetracycline resistance mediated by the efflux pump Tap from Mycobacterium fortuitum J. Antimicrob. Chemother., February 1, 2006; 57(2): 252 - 259. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. A. Weinstein, T. Yano, L.-S. Li, D. Avarbock, A. Avarbock, D. Helm, A. A. McColm, K. Duncan, J. T. Lonsdale, and H. Rubin Inhibitors of type II NADH:menaquinone oxidoreductase represent a class of antitubercular drugs PNAS, March 22, 2005; 102(12): 4548 - 4553. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Mattana, G. Biancu, L. Alberti, A. Accardo, G. Delogu, P. L. Fiori, and P. Cappuccinelli In Vitro Evaluation of the Effectiveness of the Macrolide Rokitamycin and Chlorpromazine against Acanthamoeba castellanii Antimicrob. Agents Chemother., December 1, 2004; 48(12): 4520 - 4527. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. I. M. Boshoff, T. G. Myers, B. R. Copp, M. R. McNeil, M. A. Wilson, and C. E. Barry III The Transcriptional Responses of Mycobacterium tuberculosis to Inhibitors of Metabolism: NOVEL INSIGHTS INTO DRUG MECHANISMS OF ACTION J. Biol. Chem., September 17, 2004; 279(38): 40174 - 40184. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Ordway, M. Viveiros, C. Leandro, R. Bettencourt, J. Almeida, M. Martins, J. E. Kristiansen, J. Molnar, and L. Amaral Clinical Concentrations of Thioridazine Kill Intracellular Multidrug-Resistant Mycobacterium tuberculosis Antimicrob. Agents Chemother., March 1, 2003; 47(3): 917 - 922. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Loddenkemper, D. Sagebiel, and A. Brendel Strategies against multidrug-resistant tuberculosis Eur. Respir. J., July 1, 2002; 20(36_suppl): 66S - 77s. [Abstract] [Full Text] [PDF]
|
|